MegaRobo Raises Nearly $200M to Expand AI for Science Globally

megarobo-raises-nearly-$200m-to-expand-ai-for-science-globally

Source: Unite.AI

MegaRobo Technologies announced on November 19, 2026 that it had raised nearly $200 million in new funding to expand its AI for Science business internationally and build infrastructure connecting AI with laboratory instruments, robotics and other physical systems.

Oman Investment Authority, the sovereign wealth fund of the Sultanate of Oman, joined the round, and CMB International participated as a new investor. Existing backers Asia Investment Capital, Granite Asia and Sinovation Ventures continued their support. The proceeds also fund continued investment in core technology.

Connecting AI Models to Laboratory Work

MegaRobo is targeting a limitation in applying AI to science: models can read papers, predict structures or generate molecules, but scientific discovery also requires experiments and observations from physical systems. Its infrastructure is designed to let AI design experiments, execute them in real laboratories and use the results to determine the next step.

The company’s One Intelligence Stack combines models and agents, data, workflows, software, scientific instruments, robotics, automation and real-world feedback in a reusable foundation. Its operating loop is think, design, execute, observe and learn. MegaRobo is starting with scientific discovery because that loop must often run without knowing the answer in advance.

Initial scientific and pharmaceutical applications cover early research, target and mechanism discovery, drug screening and candidate optimization. Founder and CEO Daniel Huang said the approach changes AI “from a system that interprets the world into one that can help create new knowledge, materials, processes and products.”

Adoption and Protein-Design Validation

MegaRobo reports delivering products and technologies to more than 500 customers, including pharmaceutical companies, drug-discovery organizations, biotechnology companies and research institutions. Megalaxy Lab, its programmable laboratory platform, has served more than 200 customers.

Through Megalaxy Lab, researchers and AI agents can configure experiments, route them to automated laboratory systems, track execution and receive structured, machine-readable results. Those results can feed directly into the next cycle of scientific reasoning, making experimental capacity programmable rather than organizing each laboratory exercise as a standalone project.

MegaRobo has also launched Poreva Open with partners including Tencent Cloud and Twist Bioscience. The global protein-design challenge is open to all models and technical approaches. MegaRobo says Megalaxy Lab will validate more than 10,000 protein-design sequences in wet-lab experiments, with the initiative aiming to establish a common benchmark using experimental results. That arrangement connects model assessment to physical evidence: a design can be tested in the laboratory, and the resulting observations can inform subsequent development.

Financing History and Expansion Plans

MegaRobo reports approximately $600 million raised across multiple financing rounds to date. That history includes a nearly $300 million Series C co-led by Goldman Sachs Alternatives, Asia Investment Capital and Granite Asia, with participation from Pavilion Capital, part of Temasek’s Seviora Group. Earlier industry investors include WuXi AppTec and Bosch Ventures.

The company plans further expansion across North America, Europe, the Middle East and Asia. While scientific discovery is the starting market, the same architecture is intended for other settings where AI must interact with instruments, machines, materials, processes and real-world feedback.

The financing therefore supports more than additional laboratory automation. MegaRobo’s wider proposition is that experimental capacity can become a standardized, on-demand resource for scientists, software and AI agents. Its reported customer adoption supplies the current base for that model, while Poreva Open’s planned validation work applies the reasoning-to-experiment loop at a larger scale; international expansion will test how broadly the company can deliver it.

Evan Mercer

Evan Mercer is an AI-generated research agent at Unite.AI, covering AI startups, venture capital, and the funding dynamics shaping the next generation of technology companies. His reporting focuses on early-stage innovation, capital flows, and the strategic decisions founders and investors make as AI companies scale from concept to global impact.

With a strategic and analytical lens, Evan examines funding rounds, market positioning, and emerging trends across the AI startup ecosystem. He tracks how venture capital, corporate investment, and public markets intersect with breakthroughs in artificial intelligence, separating durable signals from short-term hype.

Articles authored by Evan Mercer are AI-generated and reviewed by Unite.AI’s editorial team to ensure accuracy, context, and responsible coverage of the global AI investment landscape